Developer · ACIU · Switzerland

AC Immune SA

acimmune.com ↗

1compound
1program
1indication
Discontinuedlead asset

Phase distribution

  • Discontinued1

Modality

  • Biologic 1

Mechanism focus

Pipeline (1)

Deals & partnerships

Catalysts · 0 upcoming · 4 reported

Recently reported

  • 2026-02-01missed

    CrenezumabforAlzheimer's diseaseFull results

    API ADAD Colombia full results published in The Lancet Neurology: no significant slowing of cognitive decline in PSEN1 E280A carriers treated 5-8 years; crenezumab retained a benign ARIA profile consistent with its IgG4 design.

    source ↗

  • 2022-06-16missed

    CrenezumabforAlzheimer's diseaseTopline data

    API ADAD Colombia prevention trial missed both co-primary endpoints in cognitively unimpaired PSEN1 E280A carriers; small numerical differences favored crenezumab but did not approach significance.

    source ↗

  • 2019-01-30missed

    CrenezumabforAlzheimer's diseaseInterim analysis

    CREAD 1/2 discontinued: the IDMC's preplanned interim analysis showed crenezumab 60 mg/kg IV q4w was unlikely to meet the CDR-SB primary endpoint in prodromal-to-mild Alzheimer's disease; no safety signal.

    source ↗

  • 2014-07-16missed

    CrenezumabforAlzheimer's diseaseTopline data

    ABBY and BLAZE Phase 2 trials missed their primary endpoints in mild-to-moderate Alzheimer's disease; an exploratory trend in milder patients at 15 mg/kg IV motivated the CREAD dose escalation.

    source ↗

Recent activity

  • Feb 1, 2026ReadoutCrenezumab·Alzheimer's diseasemissedAPI ADAD Colombia full results published in The Lancet Neurology: no significant slowing of cognitive decline in PSEN1 E280A carriers treated 5-8 years; crenezumab retained a benign ARIA profile consistent with its IgG4 design.source ↗
  • Jun 16, 2022ReadoutCrenezumab·Alzheimer's diseasemissedAPI ADAD Colombia prevention trial missed both co-primary endpoints in cognitively unimpaired PSEN1 E280A carriers; small numerical differences favored crenezumab but did not approach significance.source ↗
  • Jan 30, 2019ReadoutCrenezumab·Alzheimer's diseasemissedCREAD 1/2 discontinued: the IDMC's preplanned interim analysis showed crenezumab 60 mg/kg IV q4w was unlikely to meet the CDR-SB primary endpoint in prodromal-to-mild Alzheimer's disease; no safety signal.source ↗
  • Mar 22, 2016Phase changeCrenezumab·Alzheimer's diseasePhase 3CREAD (NCT02670083, BN29552) started per ClinicalTrials.gov: Phase 3, randomized, double-blind, placebo-controlled study of crenezumab 60 mg/kg IV q4w — four times the highest Phase 2 dose — in prodromal-to-mild Alzheimer's disease (813 randomized). CREAD 2 (NCT03114657, BN29553, 806 randomized) followed on 2017-03-29, and the BN40031 open-label extension opened 2018-04-11.source ↗
  • Jul 16, 2014ReadoutCrenezumab·Alzheimer's diseasemissedABBY and BLAZE Phase 2 trials missed their primary endpoints in mild-to-moderate Alzheimer's disease; an exploratory trend in milder patients at 15 mg/kg IV motivated the CREAD dose escalation.source ↗
  • Dec 20, 2013Phase changeCrenezumab·Alzheimer's diseasePhase 2API ADAD Colombia trial (NCT01998841, GN28352) started per ClinicalTrials.gov: the first-ever anti-amyloid prevention trial in autosomal-dominant Alzheimer's disease — 252 cognitively unimpaired members of the Colombian PSEN1 E280A kindred randomized to crenezumab or placebo for five to eight years, run by Genentech with Banner Alzheimer's Institute and the National Institute on Aging. ABBY and BLAZE read out in 2014 having missed their primary endpoints; dose-escalation modeling from their exploratory analyses shaped the later Phase 3 dose.source ↗
  • Apr 30, 2011Phase changeCrenezumab·Alzheimer's diseasePhase 2ABBY (NCT01343966, ABE4869g) started per ClinicalTrials.gov: Phase 2, randomized, double-blind, placebo-controlled study of MABT5102A in 448 patients with mild-to-moderate Alzheimer's disease (300 mg SC q2w or 15 mg/kg IV q4w vs placebo). The biomarker study BLAZE (NCT01397578, ABE4955g, n=91) followed on 2011-08-31. Phase 1 studies preceded; this row starts the pivotal record.source ↗

Competitive landscape

Other companies developing against AC Immune SA's targets or indications.